AstraZeneca (NASDAQ: AZN), a U.K.-based pharmaceutical giant, is one of them; its stock is up by an impressive 16% since ...

Independent Advisor Alliance increased its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 13.0% in the fourth ...

Wealthfront Advisers LLC acquired a new stake in AstraZeneca PLC (NASDAQ:AZN – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange ...

All the latest breaking news on United States. Browse ibtimes archives of photos, videos and articles on United States.

A new sub-analysis of data from a phase 3 trial shows AstraZeneca’s Brilinta cuts the risk of cardiovascular death by 29% in high risk patients. The new study will be presented at the European ...

Drug firm AstraZeneca Pharma India Ltd on Friday (March 7) said it has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import, sell, and distribute durvalumab ...

The FDA has granted a fast review of AstraZeneca’s cardiovascular diseases drug Brilinta (ticagrelor) in the new indication that aims to reduce the chances of patients having recurring strokes.

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...

As­traZeneca wasn’t ex­pect­ed to have da­ta from the Phase 3 tri­al of its oral SERD un­til the sec­ond half of this year so the pos­i­tive … ...

AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim analysis. The trial hit on progression-free survival (PFS), its ...